RecruitingPhase 1NCT07049575

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Sponsor

Incyte Corporation

Enrollment

24 participants

Start Date

Nov 3, 2025

Study Type

INTERVENTIONAL

Conditions

Hidradenitis Suppurativa

Summary

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Eligibility

Min Age: 12 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ruxolitinib Cream for people with hidradenitis suppurativa. The study is currently recruiting participants at 21 locations. People eligible for this study include aged 12 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRuxolitinib Cream

Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Locations(21)

Saguaro Dermatology

Phoenix, Arizona, United States

First Oc Dermatology

Fountain Valley, California, United States

Amicis Research Center Valencia

Northridge, California, United States

Children'S Hospital of Orange County

Orange, California, United States

Clinical Trials Research Institute

Thousand Oaks, California, United States

Clarity Dermatology

Castle Rock, Colorado, United States

International Clinical Research Tennessee Llc

Sanford, Florida, United States

Lenus Research Medical Group, Llc

Sweetwater, Florida, United States

Trueblue Clinical Research

Tampa, Florida, United States

Lane Dermatology and Dermatologic Surgery

Columbus, Georgia, United States

Options Research Group, Llc

West Lafayette, Indiana, United States

Equity Medical, Llc

Bowling Green, Kentucky, United States

Delricht Research

Baton Rouge, Louisiana, United States

Revival Research Institute, Llc Troy

Troy, Michigan, United States

Red River Research Partners

Bolivar, Missouri, United States

Dr Bobby Buka, Md Greenwich Village

New York, New York, United States

Equity Medical, Llc

New York, New York, United States

Red River Research Partners

Fargo, North Dakota, United States

Centricity Research Columbus

Columbus, Ohio, United States

Unity Clinical Research

Oklahoma City, Oklahoma, United States

Paddington Testing Co Inc

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07049575

Related Trials

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT0688819314 locations

Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI)

NCT06368388

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

NCT076654374 locations

Targeting Nociceptors in Hidradenitis Suppurativa

NCT054037101 location

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

NCT060585201 location